Clinical Value of PET/CT in Staging Melanoma and Potential New Radiotracers-Reference-Cited by-同舟云学术

Clinical Value of PET/CT in Staging Melanoma and Potential New Radiotracers

Published:2020-03-13 Issue:1 Volume:13 Page:6-13
ISSN:1874-4710
Container-title:Current Radiopharmaceuticals
language:en
Short-container-title:CRP

Author:

Annunziata Salvatore¹^ORCID,Laudicella Riccardo²,Caobelli Federico³,Pizzuto Daniele A.⁴,Aimn Working Group Young⁵

Affiliation:

1. Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, Italy

2. Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina ME, Italy

3. Department of Nuclear Medicine, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland

4. Department of Nuclear Medicine, University Hospital Zurich/University of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland

5. Executive Committee of the Italian Association of Nuclear Medicine, Milan, Italy

Abstract

Background:18F-FDG PET/CT has been suggested as an effective tool to stage patients affected by melanoma. In the latest years, new radiopharmaceuticals have been proposed and the use of hybrid PET/ceCT has emerged.Objective:To review recent evidence on the role of PET/CT in melanoma staging as well as its potential for future developments.Methods:A comprehensive computer literature search of PubMed/MEDLINE was carried out to find relevant published articles concerning the feasibility of PET/CT in patients with malignant melanoma.Results:Some recent studies about potentials and limitations of 18F-FDG PET/CT in staging melanoma, new PET radiotracers beyond 18F-FDG and application of hybrid PET/ceCT have been reviewed and discussed.Conclusion:PET/CT plays an important role in the staging workup of patients affected by melanoma. New radiopharmaceuticals and hybrid PET/ceCT could improve the potential of this diagnostic tool in this field.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Radiology, Nuclear Medicine and imaging

Reference28 articles.

1. Krug B.; Crott R.; Lonneux M.; Baurain J.F.; Pirson A.S.; Vander Borght T.; Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology 2008,249(3),836-844

2. Schröer-Günther M.A.; Wolff R.F.; Westwood M.E.; Scheibler F.J.; Schürmann C.; Baumert B.G.; Sauerland S.; Kleijnen J.; F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. Syst Rev 2012,1,62

3. Chandra P.; Purandare N.; Shah S.; Agrawal A.; Puri A.; Gulia A.; Rangarajan V.; Diagnostic Accuracy and Impact of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Preoperative Staging of Cutaneous Malignant Melanoma: Results of a Prospective Study in Indian Population. World J Nucl Med 2017,16(4),286-292

4. Singnurkar A.; Wang J.; Joshua A.M.; Langer D.L.; Metser U.; 18F-FDG-PET/CT in the Staging and Management of Melanoma: A Prospective Multicenter Ontario PET Registry Study. Clin Nucl Med 2016,41(3),189-193

5. Ortega-Candil A.; Rodríguez-Rey C.; Cano-Carrizal R.; Cala-Zuluaga E.; González Larriba J.L.; Jiménez-Ballvé A.; Fuentes-Ferrer M.E.; Cabrera-Martín M.N.; Pérez-Castejón M.J.; García García-Esquinas M.; Lapeña-Gutierrez L.; Carreras-Delgado J.L.; Breslow thickness and (18)F-FDG PET-CT result in initial staging of cutaneous melanoma: Can a cut-off point be established? Rev Esp Med Nucl Imagen Mol 2016,35(2),96-101

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic value of 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in acral melanoma–predominant Asian patients;Journal of the Chinese Medical Association;2023-09-22

2. Uveal Melanoma Metastasis to the Thyroid;Case Reports in Endocrinology;2023-08-16

3. ¹⁸F-5-FPN: A Specific Probe for Monitoring Photothermal Therapy Response in Malignant Melanoma;Molecular Pharmaceutics;2022-11-16

4. MC1R and melanin-based molecular probes for theranostic of melanoma and beyond;Acta Pharmacologica Sinica;2022-08-25

5. Role and Place of PET/CT in the Assessment of Skin Melanoma Prevalence;Journal of radiology and nuclear medicine;2022-07-09